OS of patients diagnosed with high-risk DLBCL treated with atezolizumab consolidation and a 1:1 matched population-based control group from the NCR. IKNL, Netherlands Comprehensive Cancer Organization; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone.